Facebook
X
LinkedIn
Forward
6th Annual Conference on Psychedelics and Psychedelic Medicine
We invite you to join us at the Starr Center at Massachusetts General Hospital in Boston for our 6th Annual Conference on Psychedelics and Psychedelic Medicine!
Please Note: The conference will be held in Eastern Daylight Time (EDT)
Course Director Franklin King, MD, presents this annual conference as a clinically focused examination of the rapidly evolving field of psychedelic medicine. The program offers up-to-date overviews and critical discussions of current research in psychedelics and psychedelic-assisted therapies, with a clear emphasis on clinical evidence and real-world practice. Sessions will explore proposed mechanisms of action—including pharmacology, neuroscience, and psychodynamic frameworks—while grounding these concepts in the treatment of specific clinical conditions such as depression, PTSD, and substance use disorders. In addition, expert panels and presentations will address ethical considerations, historical context, cultural perspectives, and the role of plant-based medicines, providing clinicians with a balanced, academically rigorous view of this emerging therapeutic landscape.
Virtual Registration
We are also offering a full virtual option to accommodate those who can not attend in person.
For more information and to register, please click the link below.
Register for 2026 Virtual Psychedelics
Pricing
MDs/Doctoral-Level Professionals:
Super Early Bird (on or before June 15, 2026): $525
Early Bird (on or before July 31, 2026): $575
Regular Registration (after July 31, 2026): $600
Other Clinicians:
Super Early Bird (on or before June 15, 2026): $425
Early Bird (on or before July 31, 2026): $475
Regular Registration (after July 31, 2026): $500
Other Professionals: $150.00
Trainees/Students: $100.00
Printed Syllabus
Price: $75.00 (Please note, all syllabus purchases are non-refundable and non-shippable and must be picked up onsite at the conference)
The conference syllabus is a printed book with all slide presentations and space to take notes adjacent to each slide. As an alternative to purchasing a conference syllabus, we provide all attendees with completely free access to all slide presentations in digital PDF format prior to the conference. This is an environmentally friendly alternative and helps keep costs lower for all attendees.
E-Syllabus
We provide all attendees with completely free access to all slide presentations in digital PDF format prior to the conference. This is an environmentally friendly alternative and helps keep costs lower for all attendees. The e-syllabus will be available for 30 days after the conference.
Livestream Troubleshooting Tips.pdf
Cancellation Policy
A refund minus a $100.00 administrative fee will be issued for refund requests received by October 3, 2026. No refunds will be issued for refund requests made after October 3, 2026. Payments made may not be applied to future conferences or other educational activities. There are no exceptions to these policies.
Target Audience
This program is designed for clinicians and researchers across various disciplines who are interested in deepening their understanding of psychedelics, both theoretically and practically. It is open to mental health practitioners such as psychiatrists, psychiatric nurse practitioners, social workers, and clinical psychologists, as well as professionals from other fields who are curious about the applications of psychedelics in clinical and research settings.
Learning Objectives
By the end of this program, participants will be able to:
- Compare different models of psychedelic-assisted psychotherapy (eg, psycholytic vs psychedelic).
- Identify the potential risks of psychedelic-assisted therapies.
- Identify the training and education programs and protocols for Psychedelic Assisted therapies.
- Explain the neuropsychopharmacology of classical psychedelics, as well as atypical psychedelics such as ketamine and empathogens such as MDMA.
- Identify the neuropsychopharmacology of classical psychedelics, as well as atypical psychedelics such as ketamine and empathogens such as MDMA.
- Identify hypotheses for mechanisms of action of psychedelics on the brain, based on recent neuroimaging studies.
- Identify contemporary medico-cultural issues within psychedelic research.
- Critique contemporary medico-cultural issues within psychedelic research, including race-based structural biases and epistemic injustice.
- Identify race-based structural biases and epistemic injustice in psychedelic research.
- Assess potential applications of psychedelic-assisted therapy in extra-psychiatric fields, such as within palliative care and spirituality, as well as within medicine, such as for pain and immunomodulation.
- Discuss the ethical considerations and frameworks necessary for conducting research with psychedelic substances.
- Analyze the current regulatory landscape for psychedelic therapies and their implications for clinical practice.
Accreditation
Check Back Soon for Accreditation Information.
6th Annual Conference on Psychedelics & Psychedelic Medicine
November 13-14, 2026
MGH Starr Center, Boston
Friday, November 13th
8:30 – 8:35 AM Welcome & Introduction
Franklin King, MD
Module 1: Introduction and Keynote
8:35 – 8:55 AM Psychedelic Pharmacology for Clinicians
Franklin King, MD
8:55 – 9:45 AM Keynote: Psychedelic-Assisted Therapy: Evidence, Experience, and Ongoing Questions
Stephen Ross, MD
9:45 – 10:15 AM Keynote Panel Discussion
Moderator: Franklin King, MD
Panelist: Stephen Ross, MD
10:15 – 10:30 AM Coffee Break
Module 2: Neurobiology & Brain States
10:30 – 11:00 AM Cognitive Networks and the Neuroscience of Depression Under Psychedelics
Sharmin Ghaznavi, MD, PhD
11:00 – 11:30 AM Plant Medicines and the Psychedelome
Stephen Haggarty, PhD
11:30 – 12:00 PM Advanced Meditation and the Third Wave of Meditation Research
Matthew Sacchet, PhD
12:00 – 12:30 PM Panel Discussion
Moderator: Jerry Rosenbaum, MD
Panelists: Sharmin Ghaznavi, MD, PhD; Stephen Haggarty, PhD; Matthew Sacchet, PhD
12:30 -1:30 PM Lunch Break
Module 3: Therapeutic Models
1:30 – 2:00 PM Ketamine and Esketamine in Academic Psychiatry
Cristina Cusin, MD
2:00 – 2:30 PM Ketamine-Assisted Psychotherapy and Coaching-Informed Care
Maren Nyer, MD, PhD
2:30 – 3:00 PM Psychoanalysis and Psychotherapy in Psychedelic Treatment
Roxanne Sholevar, MD
3:00 – 3:30 PM Psychedelics in Cancer Care: Update on State of Current Research
Yvan Beaussant, MD, MSc
3:30 – 4:00 PM Panel Discussion
Moderator: Franklin King, MD
Panelists: Cristina Cusin, MD; Maren Nyer, MD, PhD; Roxanne Sholevar, MD
4:00 PM Adjourn
Saturday, November 14th
8:30 – 8:35 AM Welcome & Introduction
Franklin King, MD
Module 4: Clinical Expansion, Psychosomatics, and Translational Imaging
8:35 – 9:05 AM Implementation Challenges in Psychedelic Care
Peter Hendricks, PhD
9:05–9:35 AM Psychosomatics and Psychedelics: Results from the MGH Psilocybin IBS Trial
Juliana Zambrano, MD, MPH
9:35–10:05 AM MDMA-Assisted Therapy and Simultaneous Patient-Therapist Neuroimaging in Pain
Vitaly Napadow, PhD
10:05–10:35 AM Panel Discussion
Moderator: Franklin King, MD
Panelists: Peter Hendricks, PhD; Juliana Zambrano, MD, MPH; Vitaly Napadow, PhD
10:35–10:50 AM Coffee Break
Module 5: Culture & Naturalistic Risk
10:50–11:20 AM Psychedelic Churches and Sacred Use
Jeffrey Breau, PhD
11:20–11:50 AM Population-Level Risks in Naturalistic Psychedelic Use
Grant Jones, PhD
11:50–12:20 PM Panel Discussion
Moderator: Franklin King, MD
Panelists: Jeffrey Breau, PhD; Grant Jones, PhD
12:20–1:20 PM Lunch Break
Module 6: Experience, Meaning, and Clinical Risk
1:20–1:50 PM Studying Psychedelics in Academic Medicine: Methodological and Conceptual Challenges
Franklin King, MD
1:50–2:20 PM Music in Psychedelic Therapy Sessions
Lisa Summer, PhD
2:20–2:50 PM Clinical Risks and Adverse Outcomes in Psychedelic Therapies
Kelley O’Donnell, MD, PhD
2:50–3:20 PM Panel Discussion
Moderator: Franklin King, MD
Panelists: Lisa Summer, PhD; Kelley O’Donnell, MD, PhD
3:20 - 3:30 PM Closing Remarks & Adjourn
Franklin King, MD
Hotel Accommodations:
The Liberty, A Marriott Luxury Collection Hotel
215 Charles Street, Boston, MA, 02114, US
We have arranged for a special discounted rate for our valued Psychedelics 2026 attendees. Please book by October 15, 2026, to enjoy this group rate. Room rates are subject to availability. Book now to reserve your space!
You will receive a confirmation email upon registering that will include the booking link for the room block. If you do not receive this email, please contact customer support [email protected]
Course Director:
Franklin King, MD
Director, Training and Education, Center for Neuroscience of Psychedelics, Massachusetts General Hospital
Instructor in Psychiatry, Harvard Medical School
Speakers:
Franklin King, MD
Director, Training and Education, Center for Neuroscience of Psychedelics, Massachusetts General Hospital
Instructor in Psychiatry, Harvard Medical School
Matthew D. Sacchet, PhD
Associate Professor, Department of Psychiatry, Harvard Medical School
Director, Meditation Research Program, Massachusetts General Hospital
Maren Nyer, MD, PhD
Clinical Psychologist & Director of Yoga Research, Massachusetts General Hospital,
Depression Clinical and Research Program (DCRP);
Assistant Professor, Harvard Medical School
Lisa Summer, PhD, LMHC, LCAT, MT-BC, FAMI
Professor Emeritus, Anna Maria College
Director/Primary Trainer, Institute for Music & Consciousness
DFCI Psilocybin Research | Supportive Oncology
MGH Psilocybin Research | GI Unit
Yvan Beaussant, MD, MSc
Assistant Professor in Medicine
Adult Palliative Care
Department of Supportive Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Stephen Ross, MD
Professor of Psychiatry and Child & Adolescent Psychiatry
Associate Director, NYU Langone Center for Psychedelic Medicine
Director, Psychedelic Medicine Research Training Program
Bellevue Hospital Center & NYU Langone Health
NYU Neuroscience Institute
NYU Grossman School of Medicine
Jeffrey Breau, PhD, MDiv.
Program Lead for Psychedelics and Spirituality
Harvard Divinity School; Center for the Study of World Religions
Sharmin Ghaznavi, MD, PhD
Massachusetts General Hospital
Center for the Neuroscience of Psychedelics
Associate Director and Scientific Director of Cognitive Neuroscience
Cristina Cusin, MD
Depression Clinical and Research Program
Director, Ketamine Clinic
Massachusetts General Hospital
Associate Professor in Psychiatry
Harvard Medical School
Peter S. Hendricks, PhD
University Professor and Heersink Endowed Chair
Director of Psychedelic Research
Department of Psychiatry and Behavioral Neurobiology
School of Medicine
University of Alabama at Birmingham
Vitaly Napadow, PhD
LAc, Professor, Harvard Medical School
Director, Schoen and Adams Discovery Center for Chronic Pain Recovery,
Spaulding Rehabilitation Hospital
Director, Center for Integrative Pain NeuroImaging (CiPNI), Martinos Center for Biomedical Imaging,
Mass General Hospital, Spaulding Rehabilitation Hospital
Grant Jones, PhD
Juliana Zambrano, MD, MPH
Attending Psychiatrist, Massachusetts General Hospital
Instructor in Psychiatry, Harvard Medical School
Stephen J. Haggarty, PhD
Director, Chemical Neurobiology Laboratory
Co-Director, MGH Precision Therapeutics Unit
Scientific Director of Neurobiology, MGH Center
for the Neuroscience of Psychedelics
Stuart & Suzanne Steele Research Scholar
Associate Professor of Neurology, Harvard Medical School
Roxanne Sholevar, MD
Staff Psychiatrist, Dana Farber Cancer Institute
Instructor in Psychiatry, Harvard Medical School
Kelley O'Donnell, MD, PhD
Clinical Associate Professor of Psychiatry, NYU Grossman School of Medicine
Director of Clinical Training, NYU Langone Center for Psychedelic Medicine